206 results about "Anti hypertension" patented technology

Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of developing insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.

The invention discloses an imidazole-5-carboxylic acids derivative and the manufacturing method. It is the angiotensin II acceptor antagon. It has strong angiotensin II antagonize activity and high blood pressure proofing activity. And it could be used as therapeutic agent to cure high blood pressure.

Methods and compositions for improving the delivery and / or efficacy of a therapy (e.g., a cancer therapy) are disclosed. In one embodiment, methods and compositions for treating or preventing a cancer (e.g., a solid tumor such as a desmoplastic tumor) by administering to a subject an anti-hypertensive agent, as a single agent or in combination with a microenvironment modulator and / or a therapy, e.g., a cancer therapy (for example, a therapeutic agent or therapy, including immunotherapy (e.g., antibodies, vaccine, cell-based), nanotherapeutics, radiation therapy, photodynamic therapy, low molecular weight chemotherapeutics, molecularly targeted therapeutics and / or oxygen radical) are disclosed.

The subject disclosure provides compositions for reducing serum cholesterol and / or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and / or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease.

The invention relates to a crystal form of azilsartan shown in formula (I) and a preparation method thereof, a pharmaceutical composition containing the crystal form, and an application of the crystal form or the pharmaceutical composition in preparing anti-hypertension medicaments.

The present invention provides methods and compositions for modulating certain metabolic processes and for treating a variety of disorders associated with metabolic syndrome, including insulin related disorders, ischemia, oxidative stress, atherosclerosis, hypertension, obesity, abnormal lipid metabolism, and stroke by administering an effective dose of a chloroquine compound. The invention also provides methods and compositions relating to administering an effective dose of a chloroquine compound in combination with at least a second pharmaceutically active ingredient or compound including an antihyperglycemic diabetes treatment, an antihypertensive agent, an antithrombotic agent, and / or an inhibitor of cholesterol synthesis or absorption.

An application of an invented medicinal composition in preparing the medicines for treating primary hypertension and protecting heart and kidney is disclosed.

The present invention relates to a pharmaceutical compound of atorvastatin or its pharmaceutically acceptable salt and an antihypertensive drug, a kit containing the compound and the use of the compound for treating patients with angina pectoris, atherosclerosis, mixed hypertension and hyperlipidemia Methods of treatment of individuals with cardiac disease and individuals with cardiac risk symptoms, including humans. The present invention also relates to a combination of atorvastatin or a pharmaceutically acceptable salt thereof and an antihypertensive agent with additive and synergistic effects, which can be used for treating angina pectoris, atherosclerosis, Individuals with mixed hypertension and hyperlipidemia and individuals with cardiac risk symptoms, including humans, are treated.

The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV-like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1–36). As a consequence of the resulting enhanced stability of the endogenous NPY (1–36) caused by the inhibition of DP IV activity, NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating anti-depressive, anxiolytic, analgesic, anti-hypertension and other neurological effects.

The invention discloses antihypertensive active tripeptide and a preparation method thereof. The amino acid sequence of the antihypertensive active tripeptide is Asn-Pro-Trp. The antihypertensive active tripeptide is obtained by hydrolyzing casein. The active tripeptide has good ACE inhibiting activity and antihypertensive function, and can be used for preparing antihypertensive drink, foods or medicine.

The invention discloses an angiotensin-converting enzyme inhibitory peptide, and a preparation method and an application thereof, wherein the amino acid sequence of the inhibitory peptide is Leu-Ala-Ser-Pro-Thr-Met. The angiotensin-converting enzyme inhibitory peptide is prepared by tracking, screening and estimating an active ingredient for inhibiting the angiotensin-converting enzyme in mactra veneriformis by virtue of modern biochemical technical means, and purifying the active ingredient by methods of enzymolysis, ultrafiltration, reversed-phase high-performance liquid chromatography and the like; and experiment results indicate that the inhibitory peptide has an excellent effect of inhibiting the angiotensin-converting enzyme and a good anti-hypertension effect, and is good in safety performance, and thus has a bright application prospect.

Apolipoprotein A-I (ApoA-I), preferably a variant form such as Apolipoprotein A-I Milano (ApoA-IM), alone or more preferably in combination with a lipid carrier such as phospholipids or other drug, can be administered locally before or during bypass surgery on diseased coronary, peripheral, and cerebral arteries, surgery to implant grafts or transplanted organs, or angioplasty, or to stabilize unstable plaques. In an alternative embodiment, the apolipoprotein is not provided directly, but the gene encoding the apolipoprotein is provided. The gene is introduced into the blood vessel in a manner similar to that used for the protein, where the protein is then expressed. The technique can also be used for delivery of genes for treatment or prevention or restenosis or other cardiovascular diseases. In yet another embodiment, stents are coated with apolipoproteins alone, apolipoproteins formulated with lipids, genetically engineered cells expressing the apolipoproteins, naked DNA coding for an apolipoprotein, or other drugs such as anti-proliferatives for local delivery to an injury site. In a preferred embodiment, the system is used with combination therapy, with for local delivery of an agent such as an apolipoprotein in combination with systemic anti-hypertension therapy, anti-inflammatoy therapy, lipid regulation and / or anti-coagulation therapy. These treatments can begin prior to, concurrent with or following local delivery.

The invention provides a composite enzymatic hydrolysis method of protein in degreased plant meal. The composite enzymatic hydrolysis method is characterized by comprising the following steps: 1) pretreatment: crushing the degreased plant meal, and sieving; 2) extraction and enzymatic hydrolysis: carrying out extraction and composite enzymatic hydrolysis on the crushed degreased plant meal, and separating solid and liquid; 3) enzyme inactivation: carrying out enzyme inactivation on a supernatant obtained in the second step, and separating solid and liquid; and 4) concentrating and drying: concentrating and drying the supernatant obtained in the third step to obtain a polypeptide product. By being detected, the polypeptide product has angiotensin-converting enzyme inhibiting activity (anti-hypertension activity), antioxidant activity, antibacterial property and anti-inflammation activity and immunity improving activity. The composite enzymatic hydrolysis method is simple in process, is easy to control, is strong in strength and is easy in large scale production.

The invention discloses an ACE inhibitory peptide and a preparation method thereof, and provides a casein hydrolysate which has an anti-hypertension effect and is rich in the ACE inhibitory peptide, the ACE inhibitory peptide with an anti-hypertension effect, and a preparation method of the ACE inhibitory peptide. The casein hydrolysate rich in the ACE inhibitory peptide contains two peptide fragments with ACE inhibitory activities; and the amino acid sequences of the two peptide fragments with ACE inhibitory activities are respectively YS and YQKFPQYLQY. The amino acid sequence of the ACE inhibitory peptide is YS or YQKFPQYLQY. The ACE inhibitory peptide or the casein hydrolysate rich in the ACE inhibitory peptide is sufficiently mixed with milk powder matrixes to prepare anti-hypertension milk powder; or the ACE inhibitory peptide or the casein hydrolysate rich in the ACE inhibitory peptide is mixed with fresh milk to obtain a mixture, and lactic acid bacteria is inoculated in the mixture to obtain yoghourt with an anti-hypertension effect. The dairy product has a remarkable anti-hypertension effect, has no influence on the normal blood pressure, is safe to eat, and is suitable for being ate by the hypertension groups.

The present invention provides methods and compositions for modulating certain metabolic processes and for treating a variety of disorders associated with metabolic syndrome, including insulin related disorders, ischemia, oxidative stress, atherosclerosis, hypertension, obesity, abnormal lipid metabolism, and stroke by administering an effective dose of a chloroquine compound. The invention also provides methods and compositions relating to administering an effective dose of a chloroquine compound in combination with at least a second pharmaceutically active ingredient or compound including an antihyperglycemic diabetes treatment, an antihypertensive agent, an antithrombotic agent, and / or an inhibitor of cholesterol synthesis or absorption.

The present invention relates to pharmaceutical compositions for reducing essential hypertension and systemic inflammation. While many drugs have been found to treat hypertension, the currently available drugs often do not maintain reduced blood pressure at the preferred norm of 115 / 75 mm Hg or less throughout a 24 hour period. The current invention provides compositions comprising at least one hypertensive drug combined with the natural product Coenzyme Q10 (ubiquinone or CoQ10), which synergizes with the antihypertensive drugs to maintain low blood pressure throughout the day and night while generating other positive effects on the risks of cardiovascular disease, renal failure, and stroke. CoQ10 also counteracts some of the side effects of some hypertensive drugs such as tiredness, weakness, and / or liver toxicity. The invention further describes therapeutically effective methods for reducing systemic inflammation in hypertensive mammals comprising treatment with an antihypertensive composition that includes at least one angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and CoQ10 (ubiquinone). The invention metrics for reducing systemic inflammation comprise the reduction of serum levels of high sensitivity C-reactive protein (CRP), Interleukin 6 (IL-6), and / or tumor necrosis factor-alpha (TNF-alpha). These antihypertensive-CoQ10 combinations will synergistically reduce both hypertension and systemic inflammation.

The invention relates to methods, compositions, and kits for combination therapy of diabetes and diabetes-related diseases and conditions (e.g., obesity). The invention finds use in patients suffering from or at risk for diabetes or diabetes-related conditions generally, and in patients also suffering from or at risk for fluid retention (e.g., edema, congestive heart failure) and / or in need of synergistic anti-inflammatory, anti-hypertensive, and anti-diabetic effect.

The invention discloses a method for preparing a hawthorn yogurt being rich in angiotensin-converting enzyme inhibition peptides. The technical scheme comprises the following steps of: adding 5%-6% of white sugar into raw milk, homogenizing and then sterilizing the raw milk at 90 DEG C for 5 minutes, and cooling the raw milk to 42-43 DEG C; inoculating 3% of a lactobacillus helveticus leavening agent and 3% of a yogurt leavening agent into the raw milk which is sterilized and then cooled; fermenting the raw milk at 41 DEG C for 3.5 hours, and then taking out to obtain the fermented milk; and crushing hawthorns to form jam, adding the jam into the fermented milk, and carrying out postmaturation so as to produce a product. The product is rich in angiotensin-converting enzyme inhibition peptides and has a unique taste and a certain anti-hypertension effect.

Compounds of the formulaare disclosed, wherein R1, represents secondary alkyl; aralkyl; cycloalkyl; heteroaryl substituted alkyl; norbornyl; and substituted secondary alkyl, aralkyl, cycloalkyl, heteroaryl substituted alkyl, norbornyl; and para-substituted phenyl groups; and R2 and R3 are hydrogen or pharmacologically acceptable acyl groups. The compounds of the invention are useful as cardiovascular vasodilator or anti-hypertensive agents. The therapeutically useful compounds of the invention as well as similar 5-N and N-6 substituted adenosine 5-uronamides are prepared, in accordance with a novel process, from isopropylidene (or otherwise suitably blocked) inosine-5'-uronic acid. Isopropylideneinosine-5'-uronic acid is reacted with a suitable inorganic acid halide, such as thionyl chloride, to yield 6-halogeno-9-[2',3'-O-isopropylidene-beta-D-ribofuranosyl-5-uronic acid halide]-9H-purine. This intermediate is reacted with an amine of the general formula R4R5NH to give a 6-halogeno substituted, substituted uronic acid amide of the formulawherein X is halogen. Reaction of the latter intermediate with an amine of the formula R1-NH2, and removal of the isopropylidene (or other) blocking groups yields the compounds of the invention.

The invention provides a gynostemma pentaphyllum paste juice jelly, and relates to a jelly with health care functions of anti-hypertension, anti-hyperlipidemia and the like. The jelly comprises the following components by weight ratio: 10-20% of gynostemma pentaphyllum paste juice, 8-20% of sugar or honey, 0.5-0.7% of thickening agent, 0.15% of antiseptic and 59.15-81.35% of water; the thickening agent is sodium alginate, agar, gelatin, carragheenan and the like; the antiseptic is citric acid, benzoic acid, sodium benzoate, sorbic acid, potassium sorbate and the like. The gynostemma pentaphyllum paste juice jelly has sweetness in bitterness and unique local flavor, has health care functions of anti-hypertension, anti-hyperlipidemia and the like, is capable of nourishing and strengthening the body, enhancing the physique and raising immunity; and is an auxiliary health care of the daily food which is suitable for patients and consumers with hypertension, hyperlipidemia and the like.

The invention discloses wheat germ drink, which mainly comprises micromolecule peptide prepared by enzymolysis of proteins of wheat germs, vitamin E and octacosanol. The invention further discloses a preparation method of the wheat germ drink. The method comprises the following steps: 1) purifying the proteins of the wheat germs, and performing two-stage enzymolysis for preparing micromolecule peptide solution; 2) adopting supercritical CO2 extraction and molecular distillation technologies for extracting and preparing the vitamin E from the wheat germs; 3) adopting the supercritical CO2 extraction and multiple crystallization technologies for extracting and preparing the octacosanol; and 4) adding Tween 80, and preparing the vitamin E and the octacosanol into emulsion. The main nutritional ingredients of the wheat germs, namely the vitamin E, the octacosanol and the proteins of the wheat germs, are separated and purified, the enzymolysis technology is used for preparing the micromolecule peptide, the vitamin E and the octacosanol are prepared into the emulsion, the three nutritional ingredients are re-combined according to a certain proportion, and auxiliary materials are further matched, thereby preparing the wheat germ drink with anti-fatigue, anti-oxidation, anti-hypertension and other functions.

The invention discloses a method for producing angiotensin converting enzyme inhibitory peptide with combined catalysis on hairtail chine, which includes the following procedures that: the hairctail chine is shattered and mixed evenly with water, with pH regulated and the temperature raised to 30-45 DEG C, added with elastase to undergo enzymatic hydrolysis, then the temperature of the hydrolysate liquid is raised rapidly to 90-100 DEG C and kept for 10-15 minutes, then cooled down rapidly to the room temperature to terminate the reaction, then the pH of the hydrolysate liquid is regualated to 1.5-3.0, which is added with pepsin for enzymatic hydrolysis, then the temperature of the reaction system is rapidly raised to 90-100DEG C, kept for 10-15 minutes, and cooled down to the room temperature rapidly to terminate the reaction, the hydrolysate liquid is centrifuged, and the supernate is harvested, condensed in vacuum, refrigerated and dried, to obtain the power-like angiotensin converting enzyme inhibitory peptide. The raw material of the invention is rich in raw material but low in price, and the technical transformation provided by the invention can improve the appendix value of hairtail chine as the residue material of processed marine products, and has importance to go on enhancing the development of the industry of processing of marine products.

The invention discloses an ACE (angiotension converting enzyme) inhibitory peptide and a preparation method thereof, and provides an ACE inhibitory peptide with an anti-hypertension effect and a preparation method of the ACE inhibitory peptide. An amino acid sequence of the ACE inhibitory peptide is YS. The preparation method comprises the following steps: sufficiently mixing the ACE inhibitory peptide with a milk powder substrate to prepare anti-hypertension milk powder; or mixing the ACE inhibitory peptide with fresh milk, and inoculating lactic acid bacteria to ferment to obtain yoghourt with the anti-hypertension effect. The milk product has a remarkable antihypertensive effect, is free of interferences on normal blood pressure, safe to eat, and suitable for the hypertension crowds.

A preparation method for anti-hypertension dried bean curd stick cookies is characterized by comprising the following raw materials, by weight, 80-90 parts of flour, 5-10 parts of corn silk powder, 5-10 parts of Chinese hawthorn powder, 5-10 parts of Laminaria japonica powder, 10-15 parts of carrots, 10-15 parts of bananas, 30-35 parts of dried bean curd sticks, 2-3 parts of dogbane leaves, 3-5 parts of oroxylum indicum, 1-2 parts of coptidis rhizome, 2-3 parts of perilla leaves, 1-2 parts of gastrodia elata, 1-3 parts of eucommia, 1-2 parts of fructus lycii, 10-15 parts of ginger, 10-15 parts of chives, 5-10 parts of mature vinegar, 3-5 parts of salt, 2-3 parts of aginomoto, and appropriate amount of palm oil. The anti-hypertension dried bean curd stick cookies are fragrant, crisp and tasty, not only have nutritional value, but also have an anti-hypertension health-care function. The corn silk can reduce blood fat, blood pressure and blood sugar, the dogbane leaves can has anti-hypertension and hypolipidemic functions on the diseases like hypertension, panasthenia and nephritis dropsy, the oroxylum indicum can whiten the skin, reduce the blood pressure and reduce the weight, and can also promote the metabolism of the human body, and the coptidis rhizome can treat hypertension and hypertension, relieve rheumatic pains, promote blood circulation, improve eyesight and calm the nerves.

The invention discloses a method for producing bioactive peptide with a high blood pressure resistant function from casein, which comprises the steps of enzymolysis reaction and the desalting of zymolyte, wherein, zymolyte in the enzymolysis reaction is casein aqueous solution; prolease Alcalase is selected as enzyme; the consumption of the enzyme is 0.072 AU / g bioactive peptide; the temperature of the whole reaction process is controlled to be 55 DEG C to 60 DEG C; the pH value is between 8.4 to 8.6; the enzymolysis time is 5 to 6 hours. The invention also discloses the casein bioactive peptide prepared through the method. The bioactive peptide has good high blood pressure resistant function, and can be used to prepare high blood pressure resistant drinks, food or medicine.

The invention discloses a reagent kit and a method for quickly detecting the polymorphism of hypertension individualized medication genes, belongs to the technical field of gene detection, and relatesto clinical anti-hypertension medicine beta 1 receptor blocker, angiotensin II receptor 1 antagonist and angiotensin converting enzyme inhibitor medicine metabolism. The reagent kit comprises sampletreatment reagents, premixed and individual-portion separately packaged gene detection reagent PCR (polymerase chain reaction) liquid 1, PCR liquid 2, PCR liquid 3, positive reference substances and negative reference substances. The sample treatment reagents are used for quickly treating human whole-blood samples. The reagent kit and the method have the advantages that the polymorphism of the hypertension individualized medication genes can be conveniently, quickly and efficiently detected by the aid of the reagent kit and the method on the basis that the detection specificity and sensitivityare guaranteed, detection operation steps can be reduced, the detection reaction time can be shortened, the production cost and the detection cost can be reduced, and the reagent kit and the method are favorable for clinical detection and analysis application.

The present invention provides a an angiotensin receptor antagonist and creatine phosphate sodium complex and uses thereof, wherein the complex comprises an angiotensin receptor antagonist and creatine phosphate sodium, a molar ratio of the angiotensin receptor antagonist to the creatine phosphate sodium is 1:1-2, and the angiotensin receptor antagonist is selected from valsartan, losartan, irbesartan, telmisartan, eprosartan, candesartan, olmesartan, saprisartan, tasosartan, and elisartan. According to the present invention, the complex is formed by compounding the angiotensin receptor antagonist and the creatine phosphate sodium, and provides the unexpected double effect and the synergistic effect for treatment of heart failure and high blood pressure, the cocrystallization salt hydrate formed by linking the hydrogen bond has the stable characteristic, the pharmacokinetic property is significantly provided, and the positive application prospects are provided in the fields of anti-high blood pressure treatment and anti-heart failure treatment.

The invention belongs to the technical field of pharmaceutical chemistry, and more specifically discloses a benzimidazole derivative, and a preparation method and pharmaceutical applications thereof. The benzimidazole derivative comprises ligustrazine and a NO donor derivative. In vivo, ligustrazine or NO can be released from the benzimidazole derivative quickly, so that effective synergistic effect with Azilsartan is achieved, anti-hypertension curative effect is improved, adverse reaction is reduced, ideal protection effect on livers and kidneys of patients is achieved, and the blank of the prior art is filled.